Superpower peptides available for pre-order. Get first access.

Peptide science

Has dermorphin been tested in humans?

Dermorphin had one clinical trial, in 150 surgical patients in 1985, plus small hormone studies. See what it found, why it stalled, and how kambo differs.

Quick answer

Yes, but in only one clinical trial. A 1985 randomized, double-blind trial gave 20 micrograms of intrathecal dermorphin to surgical patients, with mean analgesia of 43.41 hours. No follow-up trial ever ran. Small 1980s volunteer studies infused 5.5 micrograms/kg/min and measured hormone responses. Kambo exposes people to a frog-secretion mixture that contains dermorphin. Dermorphin is not FDA approved.

Published
November 12, 2026
Last updated
November 12, 2026

Dermorphin has reached only one clinical trial in humans

Dermorphin has been given to people in one randomized trial of 150 surgical patients1. A handful of small studies also infused dermorphin into volunteers and tracked their hormone responses2. Dermorphin is a peptide isolated from frog skin3 that carries an unusual D-amino acid. Dermorphin is not an FDA-approved drug4. The 1985 surgical trial is still the whole clinical story of dermorphin in humans.

One 1985 trial tested dermorphin in 150 surgical patients

The only clinical trial of dermorphin was a randomized, double-blind study in 150 consecutive patients1 after elective surgery. The trial gave dermorphin and morphine intrathecally, into the fluid-filled space around the spinal cord. Pentazocine went into a muscle instead. Researchers recorded how long pain relief lasted1 and how many patients asked for more5.

ArmDose and routeMean analgesia (hours)Patients needing extra pain relief
Dermorphin20 micrograms intrathecal43.4122%
Morphine500 micrograms intrathecal34.4558%
Pentazocine30 mg intramuscular10.7988%

Side effects showed up in every group. Urinary retention, vomiting, and headache occurred, and the rates did not differ significantly between the three groups1. One dose, by one route, on one occasion cannot establish a safety profile. The trial never examined repeated exposure or dependence. Away from the operating room, dermorphin reached a far smaller set of people.

Small 1980s studies of dermorphin in humans measured hormone responses

Outside the surgical trial, dermorphin reached volunteers in short physiology experiments that measured hormone responses to an infusion2.

A 30-minute infusion at 5.5 micrograms per kilogram per minute raised prolactin, thyrotropin, and plasma renin activity2. The same infusion increased growth hormone6 and lowered plasma cortisol7. Naloxone given beforehand blocked the thyrotropin rise8, which points to a mu-opioid receptor effect. Groups ran from six healthy men9 to 11 volunteers10, and included reproductive hormones in women11.

One study came closer to pain, raising the threshold of a spinal reflex12 in volunteers, a protective withdrawal instead of clinical pain relief. Researchers also used dermorphin as a pituitary probe, testing responses in patients with prolactinoma13 and suppressing a drug-evoked ACTH release14. None of this work grew into a development program.

Why dermorphin never advanced past the 1985 trial

No further clinical study of intrathecal dermorphin followed, and dermorphin never returned to clinical use5.

Papers citing the trial afterwards were pharmacological or review papers rather than clinical ones5. Reviewers revisiting the case found no documented reason for the stop5. Their only suggestion was commercial, that dermorphin would be less profitable than conventional opioids, which is speculation rather than a recorded cause. Today dermorphin still reaches people, through an Amazonian ritual.

Kambo exposes people to dermorphin inside a peptide mixture

Present-day exposure to dermorphin runs mostly through kambo, a practice in which the dried secretion of the Amazonian frog Phyllomedusa bicolor is applied to small burns on the skin15. Dermorphin is one peptide among many in that secretion.

The secretion holds several active peptides, and dermorphins and deltorphins bind opioid receptor systems15. Deltorphins, from the same frog skin, prefer delta over mu opioid sites16. Dried secretion runs up to 7% active peptide by weight17. The frog also makes a family of dermorphin peptides18. How much dermorphin a person receives is unknown. Kambo also sits outside medical oversight, where misuse can lead to health complications19.

The medical literature records real harm. Published cases describe acute poisoning that can be life threatening20, and a small number of deaths are recorded21. One woman reached brain death after severe hyponatremia22 following a ritual. Those outcomes belong to the secretion, not to dermorphin. In one investigated death, only deltorphin A was found in blood23.

Doping control looks for dermorphin deliberately, using validated methods for human urine samples24. The N-terminal fragment is the proposed target25, from work in liver microsomes and a zebrafish model. With a human record this short, the source of any peptide information matters.

Where can I learn about peptides?

Superpower’s peptide library covers opioid peptides such as dermorphin alongside the wider peptide families, including which compounds have been studied in people and which have not.

Every guide is written and fact-checked by a team of health journalists and licensed clinicians. The science behind peptides explains how a sequence like dermorphin's is built, tested, and classified.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to dermorphin. Dermorphin is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science